Chiarelli Nicola, Cinquina Valeria, Zoppi Nicoletta, Bertini Valeria, Maddaluno Marianna, De Leonibus Chiara, Settembre Carmine, Venturini Marina, Colombi Marina, Ritelli Marco
Division of Biology and Genetics, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.
Telethon Institute of Genetics and Medicine (TIGEM), 80078 Pozzuoli, Italy.
Biomedicines. 2024 Nov 30;12(12):2749. doi: 10.3390/biomedicines12122749.
: Dominant mutations in are known to cause vascular Ehlers-Danlos syndrome (vEDS) by impairing extracellular matrix (ECM) homeostasis. This disruption leads to the fragility of soft connective tissues and a significantly increased risk of life-threatening arterial and organ ruptures. Currently, treatments for vEDS are primarily symptomatic, largely due to a limited understanding of its underlying pathobiology and molecular mechanisms. : In this study, we conducted a comprehensive analysis of the intracellular proteome of vEDS fibroblasts, integrating these findings with our previous transcriptome results to identify key molecular pathways that drive the disease. Additionally, we explored the therapeutic potential of inhibiting miR-29b-3p as a proof of concept. : Our integrative multi-omics analysis revealed complex pathological networks, emphasizing the critical role of miRNAs, particularly miR-29b-3p, in impairing ECM organization, autophagy, and cellular stress responses, all of which contribute to the pathogenesis of vEDS. Notably, the inhibition of miR-29b-3p in vEDS fibroblasts resulted in the upregulation of several differentially expressed target genes involved in these critical processes, as well as increased protein expression of essential ECM components, such as collagen types V and I. These changes suggest potential therapeutic benefits aimed at improving ECM integrity and restoring intracellular homeostasis. : Overall, our findings advance our understanding of the complex biological mechanisms driving vEDS and lay a solid foundation for future research focused on developing targeted and effective treatment strategies for this life-threatening disorder.
已知COL3A1基因的显性突变通过损害细胞外基质(ECM)稳态导致血管性埃勒斯-当洛综合征(vEDS)。这种破坏会导致软结缔组织脆弱,并显著增加危及生命的动脉和器官破裂风险。目前,vEDS的治疗主要是对症治疗,这主要是由于对其潜在病理生物学和分子机制的了解有限。:在本研究中,我们对vEDS成纤维细胞的细胞内蛋白质组进行了全面分析,并将这些发现与我们之前的转录组结果相结合,以确定驱动该疾病的关键分子途径。此外,我们探索了抑制miR-29b-3p作为概念验证的治疗潜力。:我们的综合多组学分析揭示了复杂的病理网络,强调了miRNA,特别是miR-29b-3p在损害ECM组织、自噬和细胞应激反应中的关键作用,所有这些都促成了vEDS的发病机制。值得注意的是,在vEDS成纤维细胞中抑制miR-29b-3p导致参与这些关键过程的几个差异表达靶基因上调,以及必需ECM成分(如V型和I型胶原蛋白)的蛋白质表达增加。这些变化表明旨在改善ECM完整性和恢复细胞内稳态的潜在治疗益处。:总体而言,我们的发现推进了我们对驱动vEDS的复杂生物学机制的理解,并为未来专注于为这种危及生命的疾病开发有针对性和有效治疗策略的研究奠定了坚实基础。